Millennium reports 890,366 shares (5.6%) in TNXP

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 890,366 shares of Common Stock, representing 5.6% of the class, with the cover date 06/09/2026.

A Joint Filing Agreement dated June 12, 2026 is attached; the filing lists the filers' principal address as 399 Park Avenue, New York.

Insights

Institutional Ownership Specialist

Millennium group reports a 5.6% shared stake (890,366 shares) in TNXP.

The filing states that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander have shared voting and shared dispositive power over 890,366 shares (5.6%) as shown on the cover page dated 06/09/2026.

Ownership is aggregated via controlled entities and is accompanied by a Joint Filing Agreement dated June 12, 2026. Subsequent filings would show changes to this position.

Corporate Governance Analyst

Joint filing signals coordinated reporting, not an admission of direct beneficial ownership.

The filing includes a statement that securities are held by entities subject to Millennium's voting control and that the filers do not admit beneficial ownership. The signature block shows executive authorization by counsel and by Israel A. Englander.

Key dependencies include any later amendments or Schedule 13D filings that would change control or intent; current disclosures are limited to the shared power and the Joint Filing Agreement.

Key Figures

Shared voting/dispositive power: 890,366 shares Percent of class: 5.6% Joint Filing Agreement: dated June 12, 2026

3 metrics

Shared voting/dispositive power 890,366 shares cover page date <date>06/09/2026</date>

Percent of class 5.6% reported on cover page

Joint Filing Agreement dated June 12, 2026 Exhibit I attached to the Schedule 13G

Key Terms

shared dispositive power, beneficially owned, Joint Filing Agreement

3 terms

shared dispositive power regulatory

"Shared Dispositive Power 890,366.00"

beneficially owned regulatory

"Amount beneficially owned: See response to Item 9"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Joint Filing Agreement legal

"Joint Filing Agreement, dated as of June 12, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Millennium report in Tonix Pharmaceuticals (TNXP)?

Millennium reports shared voting and dispositive power over 890,366 shares, equal to 5.6% of common stock, per the cover page dated 06/09/2026. The ownership is shown as held by entities under Millennium's control according to the filing.

Who are the filers on the Schedule 13G for TNXP?

The filers are Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filing lists their principal address as 399 Park Avenue, New York and includes a Joint Filing Agreement dated June 12, 2026.

Does the Schedule 13G show sole voting power for the filers?

No. The filing reports 0 shares as sole voting power and 890,366 shares as shared voting power and shared dispositive power, per the cover-page responses cited in Item 5 and Item 8 of the filing.

What is the significance of the Joint Filing Agreement dated June 12, 2026?

The Joint Filing Agreement documents the filers' decision to file jointly. It formalizes coordinated disclosure among Millennium entities and Israel A. Englander; the agreement itself is attached as Exhibit I to the Schedule 13G.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:44 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tonix Pharmaceuticals Holding Corp.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

890260839

(CUSIP Number)

06/09/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 890260839

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 890,366.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 890,366.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

890,366.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 890260839

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 890,366.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 890,366.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

890,366.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 890260839

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 890,366.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 890,366.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

890,366.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tonix Pharmaceuticals Holding Corp.
(b)	Address of issuer's principal executive offices: 200 Connell Drive, Suite 3100, Berkeley Heights, New Jersey 07922
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 890260839
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/12/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/12/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	06/12/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of June 12, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.